Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it is revising downward its precedent sales and earnings guidance for the fiscal year ending September 30, 2010. This action is being taken as a result of weaker than expected overhead results for the second quarter ending March 31, 2010, based on introductory results to date. Separately, Meridian announced that it will file a 510(k) for FDA merchantry clearance next week in connection with its illumigene™ C. difficile product.

More: - The rest...